Thermo Fisher Scientific Inc., the global leader in serving science, has announced a definitive agreement to acquire Clario Holdings, Inc., a leading provider of endpoint data solutions for clinical trials. The transaction, valued at $8.875 billion in cash with additional potential earnout and performance-based payments, will be made from a shareholder group led by Astorg, Nordic Capital, Novo Holdings, and Cinven.
Clario specializes in integrating clinical trial endpoint data from multiple sources—devices, clinical sites, and patients—to help pharmaceutical and biotechnology companies collect, manage, and analyze digital evidence across every phase of drug development. Its advanced digital platform has contributed to nearly 70% of FDA drug approvals over the past decade, underscoring its pivotal role in accelerating therapeutic innovation.
Clinical trial endpoint data refers to measurable outcomes used to assess the safety and efficacy of treatments under study. As the pharmaceutical industry increasingly relies on high-quality endpoint data to ensure regulatory compliance, demonstrate therapeutic value, and guide R&D investments, Clario’s expertise has become critical to advancing evidence-based decision-making across global trials.
Clario’s portfolio includes electronic clinical outcome assessments (eCOA), medical imaging, cardiac and respiratory assessments, and wearable data capture technologies — all designed to maintain scientific accuracy and regulatory rigor in clinical outcomes research. The company operates worldwide with approximately 4,000 employees and is projected to generate around $1.25 billion in revenue in 2025.
“Clario is an outstanding strategic fit, enabling faster, more informed drug development through differentiated technology and data intelligence solutions,” said Marc N. Casper, Chairman, President and CEO of Thermo Fisher Scientific. “At Thermo Fisher, we come to work every day thinking about how we can further advance our customers’ important work, and by adding these high-growth capabilities, we will deliver even deeper clinical insights to our customers and further accelerate the digital transformation of clinical research.”
Casper further emphasized, “We’ve long admired Clario and this acquisition underscores our disciplined capital deployment strategy, which has an outstanding track record of creating shareholder value. We look forward to welcoming Clario’s colleagues to Thermo Fisher.”
Chris Fikry, M.D., CEO of Clario, said, “This strategic transaction will power the continued expansion of Clario’s differentiated digital endpoint platform and proprietary suite of AI tools. Thermo Fisher Scientific’s global scale and extensive relationships with key decision makers across large pharma and biotech will fuel expansion of our comprehensive clinical trial platform. We are certain this will benefit our clients and, ultimately, patients.”
The acquisition positions Thermo Fisher to further strengthen its leadership in digital clinical research, offering integrated data-driven solutions that support faster, more reliable, and patient-centered drug development worldwide.
Also Read